Enhancer RNAs as cancer drivers and predictive biomarkers of BET inhibitor therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1133107

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

BET inhibitors are a new type of therapy designed to slow down cancer growth by switching off cancer genes. In individuals with colon and prostate cancer, BET inhibitors have shown good initial results, but these are not long-lasting. By measuring blood levels of a specific type of RNA (a close companion of DNA), called CCAT1 and PCAT1, we hope to better understand which patients gain the most benefit from BET inhibitors, and the mechanisms that cause BET inhibitors to stop working.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Postgraduate Scholarships

Funding Amount: $124,676.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Targets

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | chromatin structure | clinical research | epigenetics | oncogenes

Related Links